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Robustness evaluationBackground and purpose: A planning target volume (PTV) in photon treatments aims to ensure that the
clinical target volume (CTV) receives adequate dose despite treatment uncertainties. The underlying sta-
tic dose cloud approximation (the assumption that the dose distribution is invariant to errors) is prob-
lematic in intensity modulated proton treatments where range errors should be taken into account as
well. The purpose of this work is to introduce a robustness evaluation method that is applicable to photon
and proton treatments and is consistent with (historic) PTV-based treatment plan evaluations.
Materials and methods: The limitation of the static dose cloud approximation was solved in a multi-
scenario simulation by explicitly calculating doses for various treatment scenarios that describe possible
errors in the treatment course. Setup errors were the same as the CTV-PTV margin and the underlying
theory of 3D probability density distributions was extended to 4D to include range errors, maintaining
a 90% confidence level. Scenario dose distributions were reduced to voxel-wise minimum and maximum
dose distributions; the first to evaluate CTV coverage and the second for hot spots. Acceptance criteria for
CTV D98 and D2 were calibrated against PTV-based criteria from historic photon treatment plans.
Results: CTV D98 in worst case scenario dose and voxel-wise minimum dose showed a very strong cor-
relation with scenario average D98 (R2 > 0.99). The voxel-wise minimum dose visualised CTV dose con-
formity and coverage in 3D in agreement with PTV-based evaluation in photon therapy. Criteria for CTV
D98 and D2 of the voxel-wise minimum and maximum dose showed very strong correlations to PTV D98
and D2 (R2 > 0.99) and on average needed corrections of 0.9% and +2.3%, respectively.
Conclusions: A practical approach to robustness evaluation was provided and clinically implemented for
PTV-less photon and proton treatment planning, consistent with PTV evaluations but without its static
dose cloud approximation.
 2019 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 141 (2019) 267–274 This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).The use of margins in photon radiotherapy is a long established
and universally adopted method to provide adequate target cover-
age under the presence of uncertainties. The CTV-PTV margin pro-
vides a geometrical buffer zone around the target within which the
desired dose is achieved for the majority of treatments; criteria of
95% of the prescription dose in 90% of the patient population has
found general appeal [1,2]. The suitability of a geometrically-
expanded buffer zone arises from the (relative) insensitivity of
megavoltage photon dose distributions to density changes in the
beam path. By and large, the biggest risk to a photon dose distribu-
tion is a geometrical miss – a translation of the CTV relative to thebeam. Therefore, the static dose cloud approximation (dose distri-
bution is invariant to errors) inherent in the PTV concept, while not
perfect, has worked well [3].
This fundamental assumption is not valid for proton therapy
(PT) [4,5] due to the relationship between the proton range and
the medium-dependent stopping power. On top of the inherent
uncertainties in predicting the stopping power [6,7], errors in pro-
ton range arise from beam path density changes due to patient set-
up or anatomy differences [8]. This range uncertainty has been
addressed by range adapted PTVs, where an extra margin is added
to the distal portion of the PTV in the beam path. This works rea-
sonably well for delivery techniques where the dose is uniform
for each of the beams [9]. With the advent of pencil beam scanning,
intensity modulated or multi-field optimised proton
therapy (IMPT) became widely available [10]. Just as its intensity
268 Practical robustness evaluation in radiotherapy – A photon andmodulated photon radiotherapy counterpart, this technique allows
uniform target coverage to be achieved using non-uniform beam
doses, leading to potentially steep inter-beam dose gradients
patched together within the target. This is where the use of a geo-
metric buffer zone breaks down, as now the range uncertainties
can lead to dose differences within the CTV itself and not just at
the periphery [11].
One method which has been developed to overcome the limita-
tions of the static dose cloud approximation is robust optimisation,
whereby deviations from the nominal (i.e. error-free) dose distri-
bution are calculated explicitly for each scenario and minimised
through the use of planning objectives [12–14]. A scenario is com-
monly called ‘error scenario’, although in this work terminology
‘treatment scenario’ is used, see next section. Since becoming
available in commercial treatment planning systems, robust opti-
misation has demonstrated the ability to improve target coverage
robustness and/or organ at risk (OAR) sparing compared to
PTV-based planning, in both proton [15–21] and photon therapy
[22–25]. It must be noted however, that robust target coverage is
generally one of many variables in the optimisation objective func-
tion and therefore is in competition with other objectives, such as
OAR dose. Therefore, there must be some evaluation of the opti-
mised plan that quantifies whether coverage criteria have been
satisfied under the specified uncertainty conditions. In PTV-based
planning there are established metrics for target coverage, such
as PTV V95%  98% prescription dose [26], which ensures a certain
probability of tumour control as well as consistency of practice and
dose reporting world-wide. There is currently no such established
metric for reporting on plan robustness, the consequence being
that any two treatment plans with similar target coverage in the
nominal scenario may behave very differently in the scenarios.
One could assess the dose distribution of each scenario but in clin-
ical practice this is unfeasible. Methods of summarising the dose
deviations in the scenarios have been investigated, including the
use of dose volume histogram uncertainty bands [27–29], error-
bar distributions [30] and root-mean-square volume histograms
[16]. While each of these methods are useful for relative compar-
isons of robustness, clearly defined target coverage acceptance
criteria, such as V95%  98% for the PTV, are lacking and while
error-bar distributions provide 3D spatial information of where
local dose deviations may occur, it is not clear how coverage can
be assessed in a PTV-like way. These limitations are not trivial
and lead to difficulties for physicians and physicists to assess the
quality of a robustly optimised plan. Furthermore, without an
established robustness metric, consistent with PTV-based evalua-
tion, how can the quality of PTV-based treatment plans be com-
pared to robustly optimised plans, especially in proton therapy
where the PTV concept is no longer adequate? This question is par-
ticularly relevant in the new era of model-based patient selection
whereby the effectiveness of different treatment modalities is
compared. In the Dutch system, PT can be indicated if a significant
clinical benefit can be expected relative to conventional photon
treatments; in this case, a difference in the normal tissue compli-
cation probability (NTCP) [31,32]. However, in order for this com-
parison to be fair, the target coverage must be comparable.
The aim of this work is to introduce a robustness evaluation
method that addresses the two main issues highlighted above: (i)
overcome the limitations of current robustness evaluation meth-
ods, and (ii) ability to universally compare target coverage under
uncertainties for any treatment modality (i.e. photons and protons)
without the use of a PTV. Perhaps most importantly, the proposed
method is consistent with current PTV practice, which provides
continuity for a radiotherapy community that relies heavily on
PTV-based clinical data [1,26,33].Materials and methods
1. Outline and terminology
The scenario-based evaluation consists of the following steps:
i. Scenario-based evaluation method: treatment scenarios are
created by sampling deviations from the generated treat-
ment plan. The dose distribution is calculated for each treat-
ment scenario.
ii. Evaluation dose distribution: Scenario dose distributions are
combined into evaluation dose distributions (described
below), so as to provide concise information for daily clinical
decision making.
iii. Acceptance criteria calibration: Dose metrics are evaluated
based on acceptance criteria, defined in a calibration proce-
dure using a set of historic treatment plans.
2. Scenario-based evaluation method
Following the definition of Tilly [34], a treatment scenario
describes a fractionated treatment with a systematic setup error
and for each fraction a random setup error. In view of computa-
tional demands, sparse sampling is used, i.e. robustness is deter-
mined for only a limited number of well-chosen worst-case
scenarios. More specifically, errors are drawn from known proba-
bility distributions and sampled at a 90% confidence level, as com-
monly used in CTV-PTV margin recipes [2] and close to the value of
85% proposed in [35].
Setup errors are modelled as rigid, uncorrelated, and normally
distributed 3D translations of the planning CT, with standard devi-
ations Rx, Ry and Rz. From integration of the 3D Gaussian distribu-
tion G(x; Rx2)G(y; Ry2)G(z; Rz2) with r32 = (x/Rx)2 + (y/Ry)2 +
(z/Rz)2, we find that r3 = 2.5 corresponds to a 90% confidence level
(Fig. 1) with r3 the length of the error vector in 3D.
Random variations in patient setup r, resulting in dose blurring
and shrinkage of the volume treated to 95% of the prescribed dose
(i.e. the V95%), are taken into account as an additional systematic
contribution. Following [2]: M = 2.5R + 1.64
p
(r2 + rp2) – 1.64 rp
with rp the penumbra width, for rp = 3.2 mm, the systematic shift
of the 95% isodose line caused by random variations can be approx-
imated by 0.7r. This way, again for computational efficiency, a
multi-fraction treatment scenario is approximated as a treatment
with only a systematic setup error.
Variations other than rigid setup errors, such as non-rigid defor-
mations, anatomical changes, intrafraction motion [36] and rota-
tions (to the extent that they are not accounted for by
translations) are beyond the scope of this paper.
Under the static dose cloud assumption, the scenario-based
approach is equivalent to a PTV-based evaluation, as illustrated
in Fig. 2, and previously found by Harrington [37].
For PT, range errors must also be taken into account, usually
modelled by scaling HUs of the planning CT. Assuming that range
errors (d) are not correlated with setup errors and are normally
distributed, range and setup errors can be combined into a 4D
Gaussian distribution r42 = (x/Rx)2 + (y/Ry)2 + (z/Rz)2 + (d/Rd)2 =
r3
2 + (d/Rd)2, where Rd is the standard deviation of range errors
(Fig. 1). Here we find that r4 = 2.8 corresponds to a 90% confidence
level, with r4 the length of the error vector in 4D. Some relevant
combinations of setup and range errors are listed in Fig. 1d. It is
recommended to use the same setup errors in treatment scenarios
for protons and photons, provided both modalities have compara-
ble setup accuracy. From Fig. 1d, it can be seen that the range error
should then be reduced from the common value of 1.5 to 1.24
times the standard deviation to keep the confidence level at 90%.
For example, a 3.5% range error that corresponds to d/Rd = 1.5
reduces to 2.9%, an adjustment that is less than differences in
Fig. 1. (a) Examples of probability distributions in 2D (green), 3D (blue) and 4D (red) simulated by taking error samples for each dimension from uncorrelated normal
distributions with standard deviations of 1. On the x axis the error radius in 2D, 3D and 4D (r2, r3 and r4, respectively), and on the y-axis the probability density. The vertical
dashed lines indicate a 90% confidence level. It can be seen that increasing the number of dimensions widens the distribution such that a constant confidence level requires
increase of the cut-off value; from 2.15 and 2.5 in 2D and 3D, to 2.8 in 4D, respectively. (b) Illustration of radius r3, the length of the vector defined by x, y, and z setup errors
relative to their standard deviations. (c) Radius r4 is defined by the r3 setup error and the range error relative to its standard deviation (d/Rd). Marks on the circle correspond to
the values given in (d). (d) Example combinations of setup and range errors with 90% confidence level. Note that increase in the setup error confidence level allows reduction
of the range error confidence while keeping the same overall confidence level. *Value for the setup error from van Herk’s paper. yValue for the range error from Paganetti’s
paper. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 2. Under the static dose cloud approximation, PTV-based and scenario-based evaluation are equivalent in terms of CTV coverage under uncertainties. In PTV-based
evaluation, the 95% isodose is static and covers the union of all translations of the CTV relative to the treatment isocentre (left image). In scenario-based evaluation, the CTV is
static and is covered by the intersection of the 95% isodoses that are computed for all translations of the isocentre (right image).
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ment scenarios with rigid shifts of the planning CT, corresponding
to directions defined on a cube, is shown in Fig. 3. Adding positive
and negative range errors to each setup error results in 28 scenar-
ios for protons and 14 for photons.
For each treatment scenario a dose distribution is calculated,
which is referred to as the scenario dose.Fig. 3. Examples of sampling setup error in a limited number of directions. Common choic
red dots), to points in between (12 blue dots), and combinations of these that result in
described in Fig. 1. The sizes of the box in x, y, and z directions may be chosen anisotropi
are more likely than in other directions. (For interpretation of the references to colour i3. Evaluation dose distribution
In order to provide meaningful yet simple methods to guide
plan assessment in daily clinical practice, the multiple scenario
dose distributions can be ‘summarised’ into an evaluation dose
distribution. For example, the voxel-wise minimum dose [38] is
the composite of minimum dose values per voxel from all sce-
narios (Fig. 4b). Alternatives include the voxel-wise mean dosees include the 6 principal directions (6 green dots), from the centre to the vertices (8
14 or 26 directions. The magnitude of the shift is equal to the error radius r3 as
c to reflect that in case of anisotropic setup uncertainties shifts in certain directions
n this figure legend, the reader is referred to the web version of this article.)
Worst scenario 
Voxel-wise min dose 
Voxel-wise mean dose 
Fig. 4. Example of the worst scenario dose, voxel wise minimum dose and voxel-wise mean dose for three scenarios (left column, higher values and brighter colours
correspond to higher dose) and a photon treatment of an oropharynx patient (CTV in blue and 95% isodose in yellow). The worst scenario is a single scenario that is selected
based on CTV dose metrics (e.g. lowest D98), the voxel-wise minimum is a composite of lowest dose per voxel in all scenarios, the voxel-wise mean dose is the scenario
average dose per voxel. The worst scenario shows how tight the dose is only on one side of the target (in one scenario), the voxel-wise min dose shows a conformal dose
whereas the voxel-wise mean dose does not correctly show how tightly the dose was planned. (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
270 Practical robustness evaluation in radiotherapy – A photon and(Fig. 4c) or to simply select the worst-case scenario dose, i.e. the
dose of the scenario with worst CTV coverage (Fig. 4a). For each
type of evaluation dose distribution, its suitability for
assessment of target coverage was determined by investigating
the correlation between the CTV V95% (or D98) to the
average V95 (or D98) of all treatment scenarios. This was done
for 842 proton and 150 photon plans (supplement). The
voxel-wise maximum dose is another evaluation dose
distribution which is more suited to identifying potential hot
spots.4. Acceptance criteria calibration
The transition from PTV-based to scenario-based evaluation
imposes the risk of introducing a systematic change in
patient treatment. This can be resolved by a calibration pro-
cedure in which correlations between evaluation parameters
for both methods are analysed for a set of historic treatment
plans. In conventional radiotherapy, PTV V95%  98% is com-
monly used [26]. McGowan et al. [39] created a database
with metrics of historically treated patients as reference for
new patient plans. Following a similar approach, correlations
between the PTV- and scenario-based metrics were deter-
mined for conversion of established acceptance criteria tothe new evaluation metrics for various photon cases (5 lung,
6 oesophagus, 8 breast and chest wall, 24 head and neck and
13 other indications).
Results
Target coverage in each of the three types of evaluation dose
distributions showed high correlations using the CTV D98 metric
(Table 1 and Figs. S3, S4b), with a slope close to unity for both pho-
ton and proton plans. In comparison, the V95 loss metric showed
weaker correlations and slopes that varied between the different
evaluation distributions and modalities (Figs. S1, S4a). The varia-
tion in slopes can be explained by the way these dose distributions
are constructed (Fig. S2). Of these, the voxel-wise minimum dose
correlated best for both modalities (R2 0.684 and 0.822 for proton
and photon plans, respectively).
Qualitatively, evaluation of the CTV coverage in the voxel-wise
minimum dose generally showed good agreement with PTV evalu-
ations in the nominal dose distribution in slice-by-slice reviews
(conceptually explained in Fig. 2 and demonstrated on patient
examples in Fig. 5a, 5b). As a consequence, the voxel-wise mini-
mum CTV D98 metric was clinically introduced for target coverage
assessment and used in the second part of this study. The voxel-
Table 1
Linear regression results of target coverage metrics (CTV V95 loss or D98) for evaluation dose distributions and scenario averages. See corresponding supplementary Figs. S1, S3
and S4).
Proton plans Photon plans
Evaluation dose metric Slope R2 Slope R2
V95 loss of voxel-wise minimum 11.2 0.684 7.83 0.822
V95 loss of worst scenario 3.44 0.617 3.13 0.565
V95 loss of voxel-wise mean 0.249 0.27 0.229 0.34
D98 of voxel-wise minimum 0.976 0.998 0.977 0.999
D98 of worst scenario dose 0.99 0.999 0.985 0.999
D98 of voxel-wise mean 1.01 0.999 1.01 1.000
Abbreviations: CTV = clinical target volume; V95 loss = percentage volume of CTV below 95% of prescribed dose; D98 = minimum dose to 98% of the volume of the CTV;
R = correlation coefficient.
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in cases with severe density inhomogeneities, like VMAT in the
thoracic region, also shown in Fig. 5b.
Fig. 5c shows examples of calibration of CTV D98 criteria of the
voxel-wise minimum dose against D98 in PTV evaluations for var-
ious indications. A strong correlation was found with a slope just
0.9% below unity. Voxel-wise maximum dose calibration against
D2 in PTV-based evaluation showed a strong correlation as well
with a slope 2.3% above unity (Fig. 5d). Scenario-based evaluations
increased D2-D98 inhomogeneity by about 3%, due to the effect of
setup error on dose variations.Discussion
Scenario-based robustness evaluation improved accuracy by
removing the static dose cloud approximation in PTV-based evalu-
ation and kept consistency with historic PTV-based evaluations.
D98 of three types of evaluation dose distributions (voxel-wise
minimum, voxel-wise mean and worst scenario) were found to
be highly correlated with scenario average metrics. Of these, the
voxel-wise minimum dose was selected as it provided valuable
spatial information, such as conformity of the high dose to the tar-
get, and allowed clinicians to judge the clinical significance of any
under-dosage just as with the traditional PTV approach. The voxel-
wise maximum dose showed locations of possible hot spots in the
target and can also be used for serial type OARs (e.g. spinal cord
and optical nervous system) to replace planning at risk volume
evaluations recommended by the ICRU.
For voxel-wise minimum and voxel-wise maximum dose distri-
butions, only small corrections to PTV-based criteria were needed,
which was defined in a calibration procedure (Figs. 5c, Fig. 5d). This
indicates that in photon treatments the static dose cloud approxi-
mation is largely true. In terms of model-based patient selection,
the calibration allowed an un-biased comparison of organ at risk
doses between proton and photon plans under comparably robust
target coverage. As such, it forms the basis of the Dutch national
consensus guidelines for proton plan evaluation. For practical rea-
sons it was chosen to allow using PTV-based evaluation for photon
plans and scenario-based evaluation in proton plans. Ideally
robustness evaluation is performed as the standard method in both
photon and proton planning since then results can be compared
directly. In a transition phase from PTV-based to scenario-based
evaluation in photon planning one could perform both evaluations
to (i) gain familiarity and confidence in scenario-based evaluation
and (ii) to obtain data for the calibration method.
A challenge is that scenario-based evaluation is computation-
ally more expensive than PTV-based evaluation where speed is
essential in a busy clinic. To keep calculation times clinically
acceptable, several approximations were made: Monotonous increase of dosimetric errors with setup error size
was assumed and no ‘intermediate’ scenarios were included.
Although Casiraghi et al. found that, for IMPT, scenarios at
cut-off values were representative [40], it is recommended to
verify this per treatment site.
 Random setup errors were converted into systematic errors for
protons the same way as for photons, based on penumbra width
rp. Although proton and photon beams may have comparable
penumbras, proton penumbras vary between machines and
with airgap for range shifter beams.
 As random errors cause dose blurring, hot-spots will reduce in
magnitude, and for evaluation of risk of hot-spots the setup
error shift should be reduced. McKenzie et al. proposed a mar-
gin of 1.3R that was either reduced or increased with 0.5r to
include the effect of dose blurring [41].
These approximations may be accounted for by acceptance cri-
teria adjustment in the calibration procedure.
Sensible error magnitudes should be defined per institution
specific to their own circumstances, as these depend on patient
setup protocols and CT calibration method. In this way the calibra-
tion to current PTV methods will result in target coverage criteria
that are neither too strict nor too loose.
A limitation of the voxel-wise minimum and maximum dose
evaluation is a lack of information of the number of scenarios
involved. There is no distinction between a hot or cold dose region
that occurs in a single or in many scenarios. A solution could be to
report the percentage of scenarios in which dose criteria are ful-
filled, as well as the scenario average (as done in this work) to
reduce sensitivity to single, unfavourable, scenarios.
Although the effect of non-rigid deformations and rotations was
not explicitly taken into account, high correlations can be expected
with setup and range uncertainties. Our clinical experience is that
IMPT plans that were optimised and evaluated to be robust against
setup/range errors were usually robust against non-rigid anatomi-
cal changes seen on repeat CT scans. Nevertheless, the described
method can easily be extended to explicitly include repeated CTs
and 4DCT scans to account for anatomical changes and breathing
motion [42]. Further developments are to remove the approxima-
tion of random setup errors as a systematic error and introduce
explicit dose calculations of fractionated, probabilistic treatment
scenario sets. This would improve accuracy but requires speed-
ups for clinical routine usage [43,44]. Finally, a probabilistic
approach is a logical development towards a higher goal of robust-
ness evaluation in terms of expected biological outcome.
In conclusion, to the best of our knowledge, the presented
Dutch consensus of robustness evaluation is the first to provide
comparable robustness of photon and proton treatments for plan-
ning comparison, and is in use in daily clinical practice. Centres
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Fig. 5. Comparison of PTV-based evaluation and robustness evaluation for various photon cases. (a–b) Examples of PTV-based evaluation (left) vs. scenario-based evaluation:
voxel-wise min (middle) and voxel-wise max (right). In (a) a head and neck VMAT (primary and elective PTV in red and pink, primary and elective CTV in orange and green
and spinal cord in blue, 95% of primary and elective dose level in orange & green) is shown and treatment scenarios in the robustness evaluation included 5 mm systematic
setup errors (including random errors converted to systematic as described in text). In (b) an esophagus VMAT (PTV in red, ITV in yellow, heart in brown and 95% dose level in
green) is shown and treatment scenarios included 8 mm systematic setup errors. 95% dose conformity to CTV in voxel-wise minimum dose agrees with 95% dose conformity
to PTV whereas voxel-wise maximum dose shows possible hot dose regions near density heterogeneities like bone (for head and neck) and lung/mediastinum. (c–d) Scatter
plots of voxel-wise minimum and maximum dose illustrates calibration of D98 and D2, respectively, with small correction factors and high correlation coefficients given in
the figure. The inset in (c) illustrates how criteria for the new (voxel-wise minimum) evaluation method can be derived from current PTV criteria and linear regression. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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